simvastatin has been researched along with Apolipoprotein B-100, Familial Defective in 230 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (8.70) | 18.7374 |
| 1990's | 98 (42.61) | 18.2507 |
| 2000's | 91 (39.57) | 29.6817 |
| 2010's | 18 (7.83) | 24.3611 |
| 2020's | 3 (1.30) | 2.80 |
| Authors | Studies |
|---|---|
| Bergamino, M; Cabaleiro-Cerviño, P; García-Giustiniani, D; García-Ibarbia, C; García-Ramos, M; González-Bustos, P; González-Lozano, J; Grana-Fernandez, A; Hernández-Hernández, JL; Monserrat-Iglesias, L; Ortíz, M; Ramudo-Cela, L; Ruíz-Martín, P; Santana-Martínez, S; Santomé-Collazo, L; Vélez-Vieitez, P | 1 |
| Grefhorst, A; Hovingh, GK; Huijgen, R; Reeskamp, LF; Stroes, ESG; Tromp, TR | 1 |
| Benaiges, D; Brea-Hernando, Á; Civeira, F; Climent, E; Lafuente, H; Marco-Benedí, V; Ortega-Martínez de Victoria, E; Pedro-Botet, J; Pintó, X; Plana, N; Suárez-Tembra, M; Vila, À | 1 |
| Ballantyne, CM; Baum, SJ; Davidson, MH; Koren, A; Langslet, G; Mandel, J; McCullough, PA; Sanganalmath, SK; Shah, PK | 1 |
| Alvez, G; Barreto-Filho, JA; Bezerra, OC; Bortoloto, LA; Brasileiro-Santos, MS; Chacra, AP; Consolim-Colombo, FM; Irigoyen, MC; Sangaleti, CT; Santos, RD | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Barbosa, SA; Fonseca, FA; Fonseca, HA; Fonzar, WT; Izar, MC; Machado, VA; Malina, DT; Santana, JM | 1 |
| Diekmann, J; Farr, M; Horstkotte, D; Mellwig, KP; van Buuren, F | 1 |
| Besseling, J; Hovingh, GK; Huijgen, R; Hutten, BA; Kastelein, JJP | 1 |
| Anderson, ML; Blasi, PR; Dunn, J; Henrikson, NB; Lozano, P; Morrison, CC; Nguyen, M; Whitlock, EP | 1 |
| Adams-Huet, B; Ahmad, Z; Khine, H; Yuet, WC | 1 |
| Casula, M; Catapano, AL; Corrao, G; Merlino, L; Scotti, L; Tragni, E | 1 |
| Michałek, A | 1 |
| Brown, WV; Harrison, DG; Raggi, P | 1 |
| Steinberg, D | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Eichhorn, EJ | 1 |
| Diamond, GA; Kaul, S | 1 |
| Connor, WE | 1 |
| Blake, JA | 1 |
| Kaye, T | 1 |
| Berthold, HK; Nitschmann, S | 1 |
| Avis, HJ; Cuffie-Jackson, C; Gagné, C; Kastelein, JJ; Shi, G; Trip, MD; van der Graaf, A; Veltri, E; Vissers, MN | 1 |
| Spence, JD | 1 |
| Basart, DC; Defesche, JC; Heeringa, J; Kastelein, JJ; Lansberg, PJ; Liem, AH; Oosterveer, DM; Sijbrands, EJ; Versmissen, J; Witteman, JC; Yazdanpanah, M | 1 |
| Farmer, JA | 1 |
| de Lorgeril, M | 1 |
| Groen, AK; Hutten, BA; Jakulj, L; Kastelein, JJ; Lutjohann, D; Veltri, EP; Vissers, MN | 1 |
| Friedrich, DA | 1 |
| Bláha, M; Bláha, V; Lánská, M; Malý, J; Nováková, L; Solich, P; Solichová, D; Vlcková, H | 1 |
| Avellone, G; Campisi, D; Di Garbo, V; Guarnotta, V; Parrinello, G; Purpura, L; Scaglione, R; Torres, D | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| de Sauvage Nolting, PR; Hutten, BA; Kastelein, JJ; Kusters, DM | 1 |
| Klaus, G; Kurt, B; Sattler, A; Schaefer, JR; Soufi, M | 1 |
| Gill, PJ; Harnden, A; Karpe, F | 1 |
| Barrett, PH; Dane-Stewart, CA; Dimmitt, SB; Mamo, JC; Martins, IJ; Redgrave, TG; Watts, GF | 1 |
| Buirma, RJ; Dallinga-Thie, GM; de Sauvage Nolting, PR; Hutten, BA; Kastelein, JJ; Twickler, MB | 1 |
| Buirma, RJ; de Sauvage Nolting, PR; Hutten, BA; Kastelein, JJ | 2 |
| Illingworth, DR; Pappu, AS | 1 |
| Bakker, HD; de Jongh, S; Dobbelaere, D; Gagné, C; Gumbiner, B; Kastelein, JJ; Lambert, M; Mercuri, M; Ose, L; Perron, P; Saborio, M; Sapre, A; Scott, R; Stepanavage, M; Szamosi, T; Tuohy, MB; van Trotsenburg, AS | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Bakker, HD; de Jongh, S; Kastelein, JJ; Lilien, MR; op't Roodt, J; Stroes, ES | 1 |
| Sinzinger, H | 1 |
| Aukrust, P; Frøland, SS; Gullestad, L; Kastelein, JJ; Pedersen, TR; Semb, AG; Smilde, T; Stalenhoef, AF; Tripp, MD; Ueland, T; van Wissen, S; Waehre, T | 1 |
| Asselbergs, FW; Gans, RO; Henneman, MM; May, JF; Smit, AJ; Tervaert, JW; van Doormaal, JJ; van Haelst, PL; van Roon, AM; Veeger, NJ | 1 |
| Brady, TJ; Derfler, K; Haas, M; Hoffmann, U; Kostner, K; Stadler, A | 1 |
| Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| Bacon, SP; Illingworth, DR; Pappu, AS | 1 |
| Amano, Y; Imura, Y; Ishikawa, E; Nishimoto, T; Sugiyama, Y; Tozawa, Ri | 1 |
| Bucek, RA; Dirisamer, A; Hachemian, N; Reiter, M; Widhalm, K; Wolf, F | 1 |
| Belowski, D; Herman, ZS; Kalina, Z; Kowalski, J; Madej, A; Okopien, B; Zielinski, M | 1 |
| de Boo, T; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Alonso, R; Badimón, J; Mata, P | 1 |
| de Groot, E; Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Wissen, S | 1 |
| Asada, H; Harada-Shiba, M; Kodama, H; Kusakabe, N; Miyagawa, S; Saito, M; Tada, Y; Yamamoto, A; Yokogawa, M | 1 |
| Benítez, S; Franco, M; López-Miranda, J; Marín, C; Ordóñez-Llanos, J; Otal, C; Paz, E; Pérez-Jiménez, F; Sánchez-Quesada, JL | 1 |
| Dreier, JP; Endres, M | 1 |
| de Grooth, GJ; Fruchart, JC; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; Smilde, TJ; Stalenhoef, AF; Van Wissen, S; Zwinderman, AH | 1 |
| Cording, SA; Newnham, HH; Rando, LP | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Tits, LJ; van Wissen, S | 1 |
| Alonso, R; Mata, N; Mata, P | 1 |
| de Groot, E; Kastelein, JJ; Sager, PT; Veltri, E | 1 |
| Bradamante, V; Busljeta, I; Metelko, Z; Muacević-Kataneca, D; Poljicanin, T; Reinec, Z; Sucić, M | 1 |
| de Graaf, J; Lemmers, HL; Stalenhoef, AF; van Himbergen, TM; van Tits, LJ | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Kostka, B; Marczyk, I; Michalska, M; Sikora, J | 2 |
| Chacra, AP; Maranhão, RC; Morikawa, A; Santos, RD; Vinagre, CC | 1 |
| de Graaf, J; Himbergen, TM; Roest, M; Stalenhoef, AF; van Tits, LJ; Voorbij, HA | 1 |
| de Bont, N; Demacker, PN; Hijmans, A; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Radermecker, RP; Scheen, AJ | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Kesäniemi, A | 1 |
| Babić, Z; Bradamante, V; Katanec, D; Muacević-Katanec, D; Poljicanin, T; Reiner, Z; Simeon-Rudolf, V | 1 |
| Padial, LR | 1 |
| Greenland, P; Lloyd-Jones, D | 1 |
| Curfman, GD; Drazen, JM; Jarcho, JA; Morrissey, S | 1 |
| Akdim, F; Bots, ML; de Groot, E; Duivenvoorden, R; Gaudet, D; Kastelein, JJ; Marais, AD; Sijbrands, EJ; Stalenhoef, AF; Stein, EA; Stroes, ES; Trip, MD; Veltri, EP; Visseren, FL; Zwinderman, AH | 1 |
| Brown, BG; Taylor, AJ | 1 |
| Stein, EA | 1 |
| Jackson, G | 1 |
| Brown, BG; Fazio, S; Guyton, JR; Polis, A; Tershakovec, AM; Tomassini, JE | 1 |
| Abrahamson, D; Detrano, RC; Franklin, SS; Henein, N; Kashyap, ML; Kukes, G; Rosenzweig, B; Teng, W; Willner, R; Wong, ND | 1 |
| Cummings, MH; Naoumova, R; Quiney, JR; Sönksen, PH; Thompson, GR; Umpleby, M; Watts, GF | 1 |
| Olbricht, CJ | 1 |
| Homma, Y; Kobayashi, T; Nakamura, H; Ozawa, H; Sakane, H; Yamaguchi, H | 1 |
| Dowell, FJ; Hamilton, CA; Lindop, GB; Reid, JL | 1 |
| de Bruin, TW; Koomans, HA; Rabelink, TJ; Stroes, ES | 1 |
| Richter, WO; Schwandt, P | 1 |
| Assadollahi, F; Beaumont, JL; Buxtorf, JC; Cavallero, E; Jacotot, B | 1 |
| Bär, PR; Erkelens, DW; Geerdink, RA; Smit, JW | 1 |
| Bargossi, AM; Battino, M; Di Giulio, R; Fiorella, PL; Gaddi, A; Grossi, G | 1 |
| Knops, RE; Kroon, AA; Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Amouyel, P; Brousseau, T; Devulder, B; Fruchart, JC; Lecerf, JM; Luc, G | 1 |
| Ceska, R; Kvasilová, M; Procházková, R; Sobra, J | 1 |
| Ceska, R; Justová, V; Jůzová, Z; Kvasilová, M; Procházková, R; Sobra, J; Wilczek, H | 1 |
| Shepherd, J | 1 |
| Davies, G; Kitano, Y; Maher, VM; Matthews, S; Mir, A; Neuwirth, C; Prescott, RJ; Rees, A; Shortt, MB; Thompson, GR | 1 |
| de Graaf, J; Demacker, PN; Stalenhoef, AF | 1 |
| Ball, M; Chisholm, A; Sutherland, W | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Hodgson, JM; Marks, SJ; Matthews, PG; Myers, KA; Wahlqvist, ML | 1 |
| Mazzanti, L; Polenta, M; Rabini, RA; Signore, R; Staffolani, R; Testa, I; Tocchini, M | 1 |
| Feher, MD; Knight, BL; Lant, AF; Mayne, PD; Patel, DD; Soutar, AK; Webb, JC | 1 |
| Bais, R; Clifton, PM; Coyle, P; Hosking, J; Kusenic, B; Nestel, PJ; Roach, PD; Thomas, DW; Wight, MB | 1 |
| De Haan, AF; Demacker, PN; Kleinveld, HA; Stalenhoef, AF | 1 |
| de Villiers, W; Graadt van Roggen, F; Jeenah, M; Marais, D; Seftel, H; September, W | 1 |
| Gudnason, V; Humphries, SE; Lloyd, JK; Muller, DP | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Balestrieri, GP; Di Stefano, O; Maffi, V; Salvi, A; Scalvini, T; Sleiman, I; Spandrio, S | 1 |
| Colette, C; Crastes De Paulet, A; Descomps, B; Farnier, M; Feillet, C; Monnier, LH; Percheron, C | 1 |
| Campagnoli, G; Dorigotti, F; Franceschini, G; Gianfranceschi, G; Pazzucconi, F; Sirtori, CR; Sirtori, M | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Foo, JI; Mamotte, CD; Sturm, M; Taylor, RR; van Bockxmeer, FM | 1 |
| Hehnke, U; Kaffarnik, H; Schwartz, T; Steinmetz, A | 1 |
| Lingenhel, A; Pilcher, G; Raal, FJ; Rubinsztein, DC; Utermann, G | 1 |
| Ganotakis, ES; Mikhailidis, DP; Winder, AF | 1 |
| Delport, R; Human, JA; Jerling, JJ; Lagendijk, J; Potgieter, HC; Ubbink, JB; Vermaak, WJ; Vorster, HH | 1 |
| de Graaf, J; Stalenhoef, AF; Stuyt, PM | 1 |
| Cheung, J; Crook, MA; Lumb, PJ; Wierzbicki, AS | 1 |
| Illingworth, DR; Laskarzewski, P; Melino, MR; Mitchel, YB; Pappu, AS; Pilcher, GJ; Raal, FJ; Stein, EA | 1 |
| Ceska, R; Petrásek, J; Sobra, J; Spácil, J | 1 |
| Keller, U; Marbet, GA; Miserez, AR; Tsakiris, DA; Wolf, F; Zulewski, H | 1 |
| Banga, JD; de Bruin, T; de Valk, H; Erkelens, W; Koomans, H; Rabelink, T; Stroes, E; van Rijn, H | 1 |
| Frants, RR; Havekes, LM; Leuven, JA; Lombardi, MP; Meinders, AE; Sijbrands, EJ; Smelt, AH; Van der Laarse, A; Westendorp, RG | 1 |
| Knight, BL; Patel, DD; Soutar, AK; Sun, XM | 1 |
| Brun, LD; Couture, P; Després, JP; Gagné, C; Gaudet, D; Lelièvre, M; Lupien, PJ; Simard, J; Szots, F | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 1 |
| de Bont, N; Demacker, PN; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Kleinjans, HA; Stalenhoef, AF; Stuyt, PM | 1 |
| Hoogerbrugge, N | 1 |
| Bianchetti, MG; Nuoffer, JM; Pfammatter, JP; Wiesmann, UN; Zenklusen, JM | 1 |
| Kirchgässler, KU; Schiffner-Rohe, J; Stahlheber, U | 1 |
| Gudnason, V; Heath, KE; Humphries, SE; Seed, M | 1 |
| de Maat, MP; Gevers Leuven, JA; Kluft, C; Mohrschladt, MF; Potter van Loon, BJ | 1 |
| Athias, A; Braschi, S; Châtenet-Duchêne, L; Courtois, M; Desrumaux, C; Farnier, M; Gambert, P; Jacotot, B; Lagrost, L; Lemort, N; Richard, JL | 1 |
| O'Grady, J; Schmid, P; Sinzinger, H | 1 |
| Kitano, Y; Thompson, GR | 1 |
| Di Giacomo, S; Lucani, G; Stefanutti, C; Vivenzio, A | 1 |
| Dominiczak, MH; Murphy, MJ | 1 |
| Pino, E; Prat, H; Román, O | 1 |
| Jonkers, GH | 1 |
| Blanco-Vaca, F; Franco, M; González-Sastre, F; Jorba, O; Ordóñez-Llanos, J; Otal-Entraigas, C; Sánchez-Quesada, JL | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Gylling, H; Ketonen, P; Kontula, K; Miettinen, TA; Turtola, H; Vuorio, AF | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 3 |
| Ikenoue, N; Okatani, Y; Wakatsuki, A | 1 |
| Donner, MG; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| de Jongh, S; Kastelein, JJ; Lansberg, PJ; Trip, MD | 1 |
| Chehne, F; Kritz, H; Schmid, P; Sinzinger, H | 1 |
| Covas, M; García-Faria, F; Marrugat, J; Sentí, M; Tomás, M; Torrents, A; Vila, J | 1 |
| Cabezas, MC; Dallinga-Thie, GM; de Valk, HW; Erkelens, DW; Jansen, H; Schreuder, PC; Twickler, TB | 1 |
| Armengod, ME; Ascaso, JF; Carmena, R; Chaves, FJ; Civera, M; García-García, AB; Real, JT | 2 |
| Elisaf, M; Miltiadous, G; Tsimihodimos, V | 1 |
| Bo, M; Fabris, F; Fiandra, U; Mercadante, G; Nicolello, MT; Piliego, T | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Alonso, R; Badimon, L; De Andres, R; Martínez-González, J; Mata, P; Villacastin, BP | 1 |
| de Maat, MP; Mohrschladt, MF; Smelt, AH; Westendorp, RG | 1 |
| deCampo, A; Kostner, GM; Schallmoser, K; Schmidt, H; Toplak, H | 1 |
| Crook, MA; Mikhalidis, DP; Reynolds, TM; Wierzbicki, AS | 1 |
| Durrington, PN | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S; Wollersheim, H | 1 |
| Keller, U; Mirsaidi, R; Miserez, AR | 1 |
| Chik, G; Lumb, PJ; Wierzbicki, AS | 1 |
| Bergeron, J; Couture, P; Gagné, C; Lelièvre, M; Lupien, PJ; Szots, F; Vohl, MC | 1 |
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| Geiss, HC; Parhofer, KG; Schwandt, P | 1 |
| Bruce, R; Crook, D; Mulcahy, D; Patterson, D; Worthington, M; Wynn, V | 1 |
| Bruce, R; Crook, D; Sidhu, M | 1 |
| Bacon, S; Illingworth, DR; Pappu, AS; Sexton, GJ | 1 |
| Kerr-Muir, M; Lewis, B; Quiney, J; Slavin, B; Watts, GF | 1 |
| Ball, MJ; Lewis-Barned, NJ | 1 |
| Haug, E; Lund, H; Norseth, J; Ose, L; Purvis, K; Rui, H; Tollefsrud, A; Viksmoen, L | 1 |
| Lee, E; Lepre, F | 1 |
| Kotze, MJ; Kriek, JA; Steyn, K; van Zyl, LJ; Weight, MJ | 1 |
| Bakker, HD; Bruin, T; Kastelein, JJ; Lansberg, PJ; Schaap, MC | 1 |
| Catapano, AL; Corsini, A; Fumagalli, R; Mazzotti, M; Romano, C; Romano, L | 1 |
| Gevers Leuven, JA; Hollaar, L; Smelt, AH; van 't Hooft, FM; van der Laarse, A; Zhao, SP | 1 |
| Johansson, J; Mölgaard, J; Olsson, AG | 1 |
| Schlienger, JL | 1 |
| Cigala, O; Della Valle, M; Malarbi, AL; Marasco, A; Pancallo, MT | 1 |
| Illingworth, DR; Pappu, AS; Prihoda, JS; Smith, FE | 1 |
| Alessandri, C; Balsano, F; Barsi, R; Basili, S; Censi, C; Cordova, C; Marotta, P; Paradiso, M; Peverini, F | 1 |
| Brocard, JJ; Keller, U; Oberhänsli, A; Riesen, WF | 1 |
| Bakker, HD; Gorter, JW; Kastelein, JJ; Lansberg, PJ; Schilte, PP | 1 |
| Desager, JP; Harvengt, C; Horsmans, Y | 1 |
| Balestrieri, G; Candrina, R; Di Stefano, O; Giustina, G; Salvi, A; Spandrio, S | 1 |
| Mol, MJ; Stalenhoef, AF | 1 |
| Kruse, W; Schlierf, G; Weber, E | 1 |
| MacDonald, JL; Mauro, VF | 1 |
| Tikkanen, MJ; Tilly-Kiesi, M | 1 |
| Erkelens, DW | 1 |
| Hagemenas, FC; Illingworth, DR; Pappu, AS | 1 |
| Aubert, I; Bauduceau, B; Chanu, B; Dachet, C; Emmerich, J; Erlich, D; Gautier, D; Jacotot, B; Rouffy, J | 1 |
| Creutzfeldt, C; Creutzfeldt, W; Seidel, D; Thiery, J; Walli, AK | 1 |
| French, J; White, H | 1 |
| Bercher, L; Bovet, P; Brunner, HR; Darioli, R | 1 |
| Burrichter, H; Geisel, J; Oette, K | 1 |
| Carlson, LA | 1 |
| Demacker, PN; Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| De Knijff, P; Erkelens, DW; Frants, RR; Gevers Leuven, JA; Havekes, LM; Mol, MJ; Schouten, J; Smit, J; Stalenhoef, AF | 1 |
| Kreisberg, R; Mantell, G; Miller, V; Shapiro, DR; Stein, E; Washington, L | 1 |
| Descoeudres, C; Girod, MA; Mordasini, R; Riesen, WF | 1 |
| Löbel, P; Schrör, K; Steinhagen-Thiessen, E | 1 |
| Behrens-Baumann, W; Creutzfeldt, C; Morawietz, A; Seidel, D; Thiery, J | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Walker, JF | 1 |
| Averna, M; Barbagallo, CM; Davì, G; Mogavero, A; Notarbartolo, A; Novo, S; Strano, A | 1 |
| Mölgaard, J; Olsson, AG; von Schenk, H | 1 |
| Erkelens, DW; Leuven, JA; Mol, MJ; Schouten, JA; Stalenhoef, AF | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM; van 't Laar, A | 1 |
| Bojanovski, D; Bojanovski, M; Canzler, H; Jochim, A; Schulzeck, P | 1 |
| Harvengt, C; Leclercq, V | 1 |
| Aubert, I; Besseau, M; Chanu, B; Charpak, Y; Dachet, C; Emmerich, J; Herlich, D; Jacotot, B; Rouffy, J | 1 |
| Armstrong, VW; Creutzfeldt, C; Creutzfeldt, W; Schleef, J; Seidel, D; Thiery, J | 1 |
| Bard, JM; Devulder, B; Douste-Blazy, P; Fruchart, JC; Harvengt, C; Lecerf, JM; Leclerc, V | 1 |
| Gevers Leuven, JA; Glatz, JF; Katan, MB; Kempen, HJ; van der Voort, HA | 1 |
| Weisweiler, P | 1 |
| Baggen, MG; Erkelens, DW; Kettner, M; Koningsberger, JC; Mol, MJ; Van Doormaal, JJ | 1 |
| Erkelens, DW; Gevers Leuven, JA; Mol, MJ; Schouten, JA; Stalenhoef, AF | 1 |
| Bacon, S; Illingworth, DR | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
12 review(s) available for simvastatin and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Biomarkers; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mass Screening; Myocardial Infarction; Observational Studies as Topic; Preventive Health Services; Simvastatin; Stroke; United States | 2016 |
Ezetimibe--an update.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hyperlipoproteinemia Type II; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin | 2009 |
Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Benefits and risks of simvastatin in patients with familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Humans; Hyperlipoproteinemia Type II; Risk Assessment; Simvastatin | 2003 |
Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.
Topics: Age of Onset; Anticholesteremic Agents; Cholesterol, LDL; Comorbidity; Coronary Disease; Drug Costs; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Regression Analysis; Risk Assessment; Simvastatin | 2005 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Simvastatin; Treatment Outcome | 2007 |
Ezetimibe plus simvastatin cardiovascular outcomes study program.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome | 2008 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Simvastatin: a review of its pharmacology and clinical use.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Simvastatin | 1991 |
Efficacy and tolerability of simvastatin (MK-733).
Topics: Adrenal Cortex; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1987 |
91 trial(s) available for simvastatin and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Plant sterol supplementation on top of lipid-lowering therapies in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipid Metabolism; Male; Middle Aged; Phytosterols; Simvastatin; Treatment Outcome | 2015 |
[Therapy of familial hypercholesterolemia with or without ezetimibe].
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Carotid Stenosis; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Simvastatin | 2008 |
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Simvastatin; Time Factors; Treatment Outcome | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial).
Topics: Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Prospective Studies; Simvastatin | 2009 |
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Intestinal Absorption; Male; Middle Aged; Phytosterols; Simvastatin; Sitosterols; Statistics as Topic | 2010 |
Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol; Cholesterol, HDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation Mediators; Italy; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Secondary Prevention; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography | 2010 |
Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia.
Topics: Apolipoprotein B-48; Apolipoproteins B; Biomarkers; Breath Tests; Carbon Isotopes; Cholesterol; Cholesterol, LDL; Chylomicrons; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Simvastatin; Triglycerides | 2002 |
Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol; Cohort Studies; Female; Genes, Dominant; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Logistic Models; Male; Middle Aged; Netherlands; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Probability; Prospective Studies; Severity of Illness Index; Simvastatin; Single-Blind Method; Statistics, Nonparametric; Treatment Outcome; Triglycerides | 2002 |
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.
Topics: Adolescent; Body Height; Body Mass Index; Child; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Sexual Maturation; Simvastatin | 2002 |
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Topics: Adult; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2002 |
Early statin therapy restores endothelial function in children with familial hypercholesterolemia.
Topics: Adolescent; Arteriosclerosis; Child; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Simvastatin; Treatment Outcome | 2002 |
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Double-Blind Method; Down-Regulation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Biomarkers; Brachial Artery; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; E-Selectin; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Male; Middle Aged; Nitroglycerin; Simvastatin; Triglycerides; Ultrasonography; Vasodilation; Vasodilator Agents | 2003 |
Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Calcinosis; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Adult; Atorvastatin; Biomarkers; Carotid Arteries; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2003 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2003 |
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Analysis of Variance; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glycoproteins; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Probability; Prognosis; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2004 |
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemi
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Media; Ultrasonography | 2004 |
Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
Topics: Adult; Aged; Butyrylcholinesterase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Simvastatin; Triglycerides | 2005 |
[The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II].
Topics: Aged; Antithrombin III; Atorvastatin; Factor X; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Aryldialkylphosphatase; Atorvastatin; Carboxylic Ester Hydrolases; Cholesterol, HDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin | 2008 |
Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS).
Topics: Aged; Anticholesteremic Agents; Calcium; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Felodipine; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Tomography, X-Ray Computed | 1995 |
Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia.
Topics: Adult; Aged; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Female; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy.
Topics: Adult; Creatine Kinase; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Myoglobin; Physical Exertion; Simvastatin | 1995 |
Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
Topics: Apolipoproteins B; Apoproteins; Blood Platelets; Cholesterol; Coenzymes; Cross-Over Studies; Electrocardiography; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Myoglobin; Oxidation-Reduction; Simvastatin; Treatment Outcome; Triglycerides; Ubiquinone | 1994 |
Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1995 |
[Simvastatin in the treatment of familial hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
Topics: Adult; Blood Component Removal; Cholestyramine Resin; Colestipol; Coronary Angiography; Coronary Artery Disease; Data Interpretation, Statistical; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoprotein(a); Lipoproteins, LDL; Lovastatin; Middle Aged; Odds Ratio; Simvastatin | 1995 |
The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
The effect of dietary fat content on plasma noncholesterol sterol concentrations in patients with familial hypercholesterolemia treated with simvastatin.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Sterols | 1994 |
Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
Topics: Adolescent; Adult; Cholesterol; Erythrocyte Membrane; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Pravastatin; Simvastatin; Sodium-Potassium-Exchanging ATPase | 1993 |
Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Simvastatin | 1993 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Fish oil supplementation in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cross-Over Studies; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Olive Oil; Plant Oils; Simvastatin; Time Factors | 1996 |
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Simvastatin; Triglycerides | 1997 |
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver; Male; Simvastatin | 1997 |
NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants.
Topics: Adult; Arginine; Cholesterol; Endothelium, Vascular; Forearm; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Nitric Oxide; Nitroprusside; Regional Blood Flow; Serotonin; Simvastatin; Vasodilation | 1997 |
Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group.
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Genotype; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Phenotype; Receptors, LDL; Simvastatin | 1998 |
Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Apolipoproteins B; Canada; Child; Cholesterol, LDL; Double-Blind Method; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Male; Point Mutation; Receptors, LDL; Simvastatin | 1998 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD11 Antigens; Cohort Studies; Cytokines; Double-Blind Method; Heptanoic Acids; Heterozygote; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipopolysaccharide Receptors; Lipopolysaccharides; Mice; Monocytes; Pyrroles; Simvastatin | 1998 |
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol, VLDL; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Safety; Simvastatin | 1998 |
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1997 |
Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin.
Topics: Adult; Aged; Carrier Proteins; Cholesterol Ester Transfer Proteins; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Reference Values; Simvastatin; Treatment Outcome | 1999 |
The familial hypercholesterolemia regression study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone.
Topics: Colestipol; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins, LDL; Prospective Studies; Simvastatin; Treatment Outcome | 1997 |
Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood.
Topics: Anticholesteremic Agents; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet, Fat-Restricted; Echocardiography; Electrocardiography; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Simvastatin | 1999 |
[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1999 |
Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Chromosome Aberrations; Chromosome Disorders; Female; Follow-Up Studies; Genes, Dominant; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Simvastatin | 1999 |
Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation.
Topics: Adolescent; Adult; Androstanols; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Esters; Female; Finland; Humans; Hyperlipoproteinemia Type II; Male; Margarine; Middle Aged; Mutation; Simvastatin; Sterols | 2000 |
Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia.
Topics: Adult; Aged; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin | 1999 |
Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Middle Aged; Postmenopause; Simvastatin; Triglycerides | 2000 |
Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hemorheology; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Immunosorbent Techniques; Lipoproteins, LDL; Male; Middle Aged; Plasma Volume; Pyrroles; Simvastatin | 2000 |
[Unaltered homocysteine levels during simvastatin therapy].
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Homocysteine; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Risk Factors; Severity of Illness Index; Sex Factors; Simvastatin; Smoking; Time Factors; Treatment Outcome; Triglycerides | 2000 |
Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Apolipoproteins; Aryldialkylphosphatase; Esterases; Female; Humans; Hyperlipoproteinemia Type II; Lipid Peroxides; Lipids; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Simvastatin | 2000 |
High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Regression Analysis; Simvastatin; Triglycerides | 2000 |
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2001 |
[Influence of FH Valencia 1 and 2 mutations of the LDL receptor gene on the response to simvastatin in subjects with molecularly defined heterozygous familial hypercholesterolemia in Spain].
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Mutation; Receptors, LDL; Simvastatin; Spain | 2001 |
Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2001 |
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Pyrroles; Simvastatin; Tunica Intima | 2001 |
Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
Topics: Adult; Aged; Apolipoproteins B; Apolipoproteins E; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Receptors, LDL; Simvastatin | 2001 |
Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Prospective Studies; Simvastatin | 2001 |
Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Apolipoproteins E; Child; Cholesterol, LDL; Double-Blind Method; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mutation; Polymorphism, Genetic; Receptors, LDL; Simvastatin | 2002 |
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).
Topics: Anticholesteremic Agents; Apolipoproteins; Creatine Kinase; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Liver Function Tests; Male; Middle Aged; Muscular Diseases; Simvastatin; Time Factors; Transaminases; Treatment Outcome; Triglycerides | 2002 |
Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoproteins; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Beneficial effect of simvastatin in patients with drug resistant familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Drug Administration Schedule; Drug Resistance; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Triglycerides | 1992 |
The cost of simvastatin therapy in treatment of hypercholesterolaemia in a hospital lipid clinic.
Topics: Anticholesteremic Agents; Drug Costs; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Middle Aged; Simvastatin | 1992 |
[Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
Topics: Anticholesteremic Agents; Cholesterol; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Simvastatin; Single-Blind Method; Transaminases; Triglycerides | 1991 |
Cortisol secretion in patients on simvastatin.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Adrenocortical function in patients on simvastatin.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Anticholesteremic Agents; Clinical Trials as Topic; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1990 |
Monitoring compliance in clinical trials.
Topics: Anticholesteremic Agents; Chronic Disease; Clinical Trials as Topic; Humans; Hyperlipoproteinemia Type II; Lovastatin; Microcomputers; Patient Compliance; Simvastatin | 1990 |
The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Heterozygote; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Leukocytes, Mononuclear; Lipoproteins; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Receptors, LDL; Simvastatin | 1990 |
Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Cataract; Cholesterol; Cholestyramine Resin; Creatine Kinase; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1990 |
Synvinolin in hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Simvastatin; Triglycerides | 1986 |
Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia.
Topics: Adult; Aged; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Random Allocation; Simvastatin; Triglycerides | 1986 |
Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1989 |
[Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin | 1988 |
Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin; Sterol O-Acyltransferase | 1988 |
Clinical experience with simvastatin compared with cholestyramine.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1988 |
127 other study(ies) available for simvastatin and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pharmacogenetics; Simvastatin | 2022 |
Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver X Receptors; Simvastatin | 2020 |
Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenotype; Registries; Rosuvastatin Calcium; Simvastatin; Spain; Treatment Outcome | 2021 |
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; PCSK9 Inhibitors; Peripheral Arterial Disease; Risk; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome | 2018 |
Statin restores cardiac autonomic response to acute hypoxia in hypercholesterolaemia.
Topics: Acute Disease; Adult; Autonomic Nervous System; Baroreflex; Blood Pressure; Female; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypoxia; Male; Middle Aged; Reflex; Simvastatin; Young Adult | 2013 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
[Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor].
Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Blood Component Removal; Codon, Terminator; Combined Modality Therapy; Coronary Disease; DNA Mutational Analysis; Ezetimibe; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Myocardial Revascularization; Receptors, LDL; Simvastatin | 2016 |
Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality.
Topics: Adult; Atorvastatin; Cause of Death; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Netherlands; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; Survival Rate; Treatment Outcome | 2016 |
Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.
Topics: Age Factors; Body Mass Index; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypertension; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Myalgia; Odds Ratio; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2016 |
Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Decision Making; Female; Follow-Up Studies; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Medication Adherence; Patient Education as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Young Adult | 2016 |
[Commentary to the article: Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43 ].
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Treatment Outcome | 2008 |
Enhanced hype.
Topics: Administration, Inhalation; Anticholesteremic Agents; Azetidines; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Information Dissemination; Simvastatin; United States | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Reproducibility of Results; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Niacin; Simvastatin | 2008 |
Is carotid intima-media thickness a reliable clinical predictor?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
Topics: Adult; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Heterozygous familial hypercholesterolemia case study.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Life Style; Male; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2010 |
Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Hemofiltration; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric; Tandem Mass Spectrometry | 2011 |
Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, LDL; Creatinine; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bilirubin; Biomarkers; Cardiovascular Diseases; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Risk Factors; Simvastatin; Young Adult | 2011 |
Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
Topics: Adult; Anticholesteremic Agents; Azetidines; Blood Component Removal; Cholesterol, LDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mutation; Pharmacogenetics; Receptors, LDL; Severity of Illness Index; Simvastatin; Treatment Outcome | 2012 |
Familial hypercholesterolaemia.
Topics: Adult; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Simvastatin | 2012 |
The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Analysis of Variance; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Circadian Rhythm; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Mevalonic Acid; Middle Aged; Periodicity; Probability; Prospective Studies; Sampling Studies; Simvastatin; Urinalysis | 2002 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Mevalonic Acid; Middle Aged; Simvastatin | 2003 |
Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Disease Models, Animal; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mice; Mice, Knockout; Oxazepines; Piperidines; Pyrroles; Rabbits; Receptors, LDL; Simvastatin; Species Specificity; Time Factors; Triglycerides | 2003 |
The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation.
Topics: Adolescent; Child; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Simvastatin; Triglycerides | 2003 |
Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia.
Topics: Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lipids; Male; Middle Aged; Simvastatin | 2003 |
[Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin | 2003 |
Homozygous familial hypercholesterolaemia: development of xanthogranuloma in a boy at puberty under long-term low-density lipoprotein apheresis and drug therapy.
Topics: Adolescent; Anticholesteremic Agents; Blood Component Removal; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Probucol; Simvastatin; Skin; Thigh; Xanthogranuloma, Juvenile | 2003 |
Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Receptors, Lipoprotein; Simvastatin; Statistics, Nonparametric; Triglycerides | 2004 |
Statin-associated rhabdomyolysis triggered by grapefruit consumption.
Topics: Adult; Anticholesteremic Agents; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Female; Furocoumarins; Humans; Hyperlipoproteinemia Type II; Inactivation, Metabolic; Rhabdomyolysis; Simvastatin | 2004 |
Successful reintroduction of statin therapy after myositis: was there another cause?
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypothyroidism; Male; Myositis; Pyrroles; Simvastatin | 2004 |
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENH
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2006 |
Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: effects of simvastatin.
Topics: Adult; Cholesterol; Esterification; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kinetics; Male; Middle Aged; Simvastatin | 2005 |
LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Genetic Carrier Screening; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2006 |
[Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy].
Topics: Adult; Aged; Antithrombin III; Biomarkers; Blood Coagulation; Cholesterol; Cholesterol, LDL; Factor X; Female; Fibrinogen; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Reference Values; Simvastatin; Statistics as Topic; Thrombin; Triglycerides | 2007 |
[Drug of the month. Ezetimibe/simvastatin tablet (Inegy)].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Simvastatin; Treatment Outcome | 2007 |
Clinical study on the effect of simvastatin on paraoxonase activity.
Topics: Adult; Aged; Aging; Anticholesteremic Agents; Aryldialkylphosphatase; Body Mass Index; Carboxylic Ester Hydrolases; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Sex Characteristics; Simvastatin | 2007 |
In brief: Zetia and Vytorin: the ENHANCE study.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Artery Diseases; Cholesterol, LDL; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2008 |
Critical lessons from the ENHANCE trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Conflict of Interest; Data Interpretation, Statistical; Drug Approval; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Mass Media; Randomized Controlled Trials as Topic; Simvastatin; Ultrasonography | 2008 |
Cholesterol lowering and ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Triglycerides; Tunica Intima; Tunica Media | 2008 |
Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Tunica Media | 2008 |
After ENHANCE: is more LDL cholesterol lowering even better?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Carotid Artery Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Lipid Metabolism; Simvastatin | 2008 |
ENHANCE: food for the ostriches.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Cholestyramine Resin; Colestipol; Combined Modality Therapy; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Topics: Age Factors; Animals; Aorta; Aorta, Thoracic; Arteriosclerosis; Carbachol; Cholesterol; Endothelium, Vascular; Heterozygote; Homozygote; Hyperlipoproteinemia Type II; Lovastatin; Phenylephrine; Rabbits; Simvastatin; Vasoconstriction; Vasodilation | 1995 |
Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication.
Topics: Adult; Arginine; Blood Pressure; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Forearm; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Infusions, Intravenous; Lovastatin; Male; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Serotonin; Simvastatin; Vasodilation | 1995 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Combined Modality Therapy; Coronary Disease; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
Familial xanthomatous hypercholesterolemia: abnormal exogenous lipid metabolism evidenced by the vitamin A test.
Topics: Adult; Apolipoproteins B; Eating; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides; Vitamin A; Wolman Disease | 1994 |
[Detection of the Arg 3500-->Gln mutation of B apolipoprotein. Value in clinical practice].
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Contraceptives, Oral, Combined; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Polymerase Chain Reaction; Simvastatin | 1995 |
[Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia].
Topics: Adult; Calcitriol; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Vitamin D | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Arteries; Blood Pressure; Body Mass Index; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Dietary Fats; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides; Ultrasonography; Weight Gain | 1993 |
Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholesterol; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Pedigree; Polymorphism, Genetic; Probucol; Receptors, LDL; Simvastatin | 1993 |
The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells.
Topics: Anticholesteremic Agents; Cholesterol; Dietary Fats; Gold Colloid; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; In Vitro Techniques; Leukocytes, Mononuclear; Lipoproteins, LDL; Lovastatin; Receptors, LDL; Simvastatin | 1993 |
Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Mutation; Receptors, LDL; Simvastatin; South Africa | 1993 |
Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia.
Topics: Base Sequence; Blotting, Southern; Child; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dietary Fats; Drug Therapy, Combination; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Molecular Sequence Data; Mutation; Pedigree; Receptors, LDL; Simvastatin | 1995 |
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Topics: Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Time Factors | 1995 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Binding, Competitive; Cells, Cultured; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Receptors, LDL; Simvastatin; Triglycerides | 1996 |
Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
Topics: Animals; Apolipoprotein B-100; Apolipoproteins A; Apolipoproteins B; Cats; Child, Preschool; Cholesterol, LDL; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Immunoblotting; Lovastatin; Male; Middle Aged; Pedigree; Phenotype; Receptors, LDL; Simvastatin; Treatment Outcome | 1997 |
Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Fibrinogen; Follow-Up Studies; Hemorheology; Humans; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Simvastatin | 1996 |
The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lovastatin; Male; Middle Aged; Simvastatin; Ubiquinone; Vitamin E | 1997 |
Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Antifungal Agents; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Ketoconazole; Lipids; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin; Treatment Outcome | 1997 |
[Favorable effect of treatment with statins on the intima of the common carotid artery in patients with familial hyperlipoproteinemia].
Topics: Anticholesteremic Agents; Carotid Artery, Common; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lovastatin; Middle Aged; Simvastatin; Tunica Intima; Ultrasonography | 1997 |
Simvastatin reduces activation of normal platelets by LDL isolated from patients with familial hypercholesterolaemia and familial defective apolipoprotein B.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Middle Aged; Platelet Activation; Simvastatin | 1997 |
Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Receptors, LDL; RNA, Messenger; Simvastatin | 1998 |
Weekly versus biweekly lipid removal and effect of statins in severe hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Simvastatin | 1998 |
The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins E; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Genotype; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Muscular Diseases; Mutation; Receptors, LDL; Simvastatin; Tendons; Xanthomatosis | 1999 |
Statins and C-reactive protein.
Topics: C-Reactive Protein; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1999 |
Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Topics: Adolescent; Adult; Creatine Kinase; Dose-Response Relationship, Drug; Exercise; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pain; Pravastatin; Prognosis; Risk Assessment; Simvastatin; Sports | 1999 |
Efficacy of statin therapy: possible effect of phenytoin.
Topics: Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Epilepsy; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Phenytoin; Pyrroles; Simvastatin | 1999 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrate; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Middle Aged; Pyrroles; Simvastatin; Tamoxifen; Treatment Outcome | 1999 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
[Familial hypercholesterolemia: recognition and prevention of cardiac complications at a young age].
Topics: Adult; Age Factors; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Arcus Senilis; Cholesterol, HDL; Cholesterol, LDL; Diagnosis, Differential; Diet, Fat-Restricted; Female; Humans; Hyperlipoproteinemia Type II; Male; Myocardial Infarction; Simvastatin | 2000 |
High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia.
Topics: Apolipoproteins; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genetic Carrier Screening; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Postprandial Period; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Retinyl Esters; Simvastatin; Triglycerides | 2000 |
Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2000 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin.
Topics: Adult; Brachial Artery; E-Selectin; Endothelium, Vascular; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Interleukin-6; Lipids; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography; Vasodilation | 2001 |
C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Osmolar Concentration; Risk Factors; Simvastatin | 2001 |
A novel splice-site mutation in intron 7 causes more severe hypercholesterolemia than a combined FH-FDB defect.
Topics: Adult; Aged; Apolipoproteins B; DNA, Recombinant; Drug Resistance; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Introns; Male; Middle Aged; Mutation; Simvastatin | 2001 |
Measurement of atherosclerosis progression.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2001 |
Rigorous detection and vigorous treatment of familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Ultrasonography | 2001 |
Development of tachyphylaxis on statin treatment.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrroles; Research Design; Simvastatin; Tachyphylaxis | 2001 |
Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Simvastatin | 2002 |
Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Simvastatin and lipoprotein(a)
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
One year experience in the treatment of familial hypercholesterolaemia with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Heterozygote; Hormones; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Single-Blind Method; Spermatozoa; Testis | 1992 |
Response to treatment with simvastatin in a compound FH heterozygote.
Topics: Adult; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1992 |
The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Child; Cholesterol; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Lymphocytes; Male; Predictive Value of Tests; Receptors, Cell Surface; Receptors, Lipoprotein; Simvastatin; Triglycerides | 1991 |
Poor response to simvastatin in familial defective apo-B-100.
Topics: Anticholesteremic Agents; Apolipoproteins B; Humans; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL; Simvastatin | 1991 |
Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Particle Size; Regression Analysis; Simvastatin; Triglycerides | 1991 |
Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Cholesterol, VLDL; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Particle Size; Simvastatin; Triglycerides | 1991 |
[Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1991 |
[Simvastatin in the treatment of hypercholesterolemia].
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cholesterol; Drug Evaluation; Eye; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Mevalonic Acid; Middle Aged; Simvastatin | 1991 |
[Effects of simvastatin on atherogenic blood lipid pattern].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1991 |
[A patient with the homozygote form of familial hypercholesterolemia].
Topics: Anticholesteremic Agents; Child; Exercise Test; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Simvastatin; Triglycerides | 1991 |
Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol.
Topics: Adolescent; Adult; Anticholesteremic Agents; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Simvastatin | 1991 |
Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Topics: Adult; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Niacin; Simvastatin | 1990 |
Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Misconceptions about cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Attitude; Cholesterol; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; New Zealand; Simvastatin | 1990 |
[Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
Topics: Aged; Anticholesteremic Agents; Apoproteins; Cholesterol; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
[HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
[A case of familial hypercholesterolemia with therapeutic difficulties].
Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin | 1990 |
The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
Topics: Adult; Apolipoproteins; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Sex Factors; Simvastatin | 1990 |
[Selective elimination of atherogenic lipoproteins using dextran-sulfate cellulose. Experiences in 2 patients with heterozygote familial hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Cellulose; Combined Modality Therapy; Dextran Sulfate; Dextrans; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Plasmapheresis; Simvastatin | 1989 |
Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Topics: Adenosine Triphosphate; Adult; Aged; Anticholesteremic Agents; Blood Platelets; Cyclic AMP; Epoprostenol; Humans; Hyperlipoproteinemia Type II; Iloprost; Lipids; Lovastatin; Middle Aged; Platelet Aggregation; Receptors, Epoprostenol; Receptors, Prostaglandin; Simvastatin; Thromboxane B2 | 1989 |
Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
Topics: Cataract; Cholesterol; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Simvastatin: the clinical profile.
Topics: Aged; Creatine Kinase; Drug Therapy, Combination; Eye; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Middle Aged; Simvastatin; Transaminases | 1989 |
Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Platelet Aggregation; Simvastatin; Thromboxane B2 | 1989 |
Cholesterol synthesis inhibitors in hyperlipidaemia.
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.
Topics: Adult; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
[Type IIa dyslipoproteinemia. Effects of simvastatin and bezafibrate on atherogenic and non-atherogenic lipoprotein particles].
Topics: Bezafibrate; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Simvastatin | 1988 |
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
Topics: Anticholesteremic Agents; Biomarkers; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Isomerism; Lovastatin; Male; Simvastatin | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |